Angiogenic gene therapy as a potential therapeutic agent in chronic osteomyelitis

Medical Hypotheses
John J Ross

Abstract

Bacterial osteomyelitis is common, and outcomes are often poor. Standard therapies fail in 31% of cases, and lower extremity amputation and loss of independent functional status are common. Innovative therapies are desperately needed, particularly in diabetic patients with peripheral vascular disease at high risk for bad outcomes. Angiogenic gene therapy is a novel, logical and promising approach in these patients. Adult bone is not well vascularized. Host inflammation and bacterial toxin production result in further loss of vascularity, and produce bone necrosis. Dead bone acts as a foreign body, and is permissive for persistent infection. Poor blood supply prevents remodeling of dead bone, delivery of antibiotics, and phagocytosis of bacteria. Therefore, angiogenic gene therapy may be a useful therapeutic agent in osteomyelitis. It is reasonable to pursue studies of angiogenic agents in established animal models of chronic osteomyelitis, not only with vascular endothelial growth factor (VEGF), but also with the powerful bone angiogenic agent, placental growth factor, as well as other agents with tissue regenerative and angiogenic potential, such as sonic hedgehog, bone morphogenetic proteins, matrix metalloproteinase-9, secre...Continue Reading

References

May 18, 1999·American Journal of Surgery·S L HillR Buse
Jul 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·John StreetEllen H Filvaroff
Sep 18, 2002·The Journal of Clinical Investigation·Hairong PengJohnny Huard
Apr 2, 2003·The Journal of Antimicrobial Chemotherapy·Alan D TiceDavid A Shoultz
Apr 15, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mikko Olavi HiltunenSeppo Ylä-Herttuala
May 27, 2003·Diabetes Care·Adam GordoisJanet Ash Tobian
Jul 23, 2003·Development·Céline ColnotJill A Helms
Dec 6, 2003·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Louise L SouthwoodC Wayne McIlwraith
Feb 19, 2004·Circulation·Rudolf KirchmairPeter Schratzberger
Sep 11, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Kengo F KusanoDouglas W Losordo
Feb 4, 2005·The Journal of Clinical Investigation·Young-sup YoonDouglas W Losordo
Nov 22, 2005·Infectious Disease Clinics of North America·Jason H Calhoun, M M Manring
Nov 22, 2005·Infectious Disease Clinics of North America·Sheldon L Kaplan

❮ Previous
Next ❯

Citations

Jun 23, 2010·Seminars in Plastic Surgery·Robert C Fang, Robert D Galiano
Oct 21, 2011·Stem Cell Research & Therapy·Gregory T Christopherson, Leon J Nesti
Apr 22, 2018·Stem Cell Research & Therapy·Alessandro PirosaRocky S Tuan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.